Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
53,514,204
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
1,475,121
-
Shares change
-
0
-
Total reported value, excl. options
-
$811,316
-
Price
-
$0.5500
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q4 2023
As of 31 Dec 2023 Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) had 1 institutional shareholder that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 1,475,121 shares of stock of the company.
Largest 10 holders included Bain Capital Life Sciences Investors, LLC, Atlas Venture Life Science Advisors, LLC, FMR LLC, Octagon Capital Advisors LP, TAKEDA PHARMACEUTICAL CO LTD, RiverVest Venture Management LLC, Rock Springs Capital Management LP, VANGUARD GROUP INC, Artal Group S.A., and Trustees of Columbia University in the City of New York.
This table shows 33 institutional shareholders of the security as of 31 Dec 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.